Document Type

Article

Publication Title

Journal of Law, Medicine, and Ethics

Publication Date

Spring 2020

ISSN

1748-720X

Page Number

129

Keywords

consent, parental permission, clinical trials, pediatric research

Disciplines

Health Law and Policy | Law

Abstract

Research with children lags far behind research with adults, even though research conducted with pediatric participants is critical to developing scientific knowledge that can benefit children. This is particularly apparent in the realm of pharmaceuticals. In a recent study, physicians prescribed an off-label medication to children in 18.5% of pediatric ambulatory care visits. In 74.6% of these cases, the medication was prescribed to treat a condition for which it did not have FDA approval, and in 17.6% of cases the medication was approved for the condition but not in the child’s age group. This widespread practice of using unapproved, and thus potentially ineffective and unsafe, medications in children continues due to longstanding challenges in stimulating pediatric research.

Numerous factors have contributed to delays in the pursuit of pediatric research. Economics has clearly played an important part in delays in pharmaceutical trials. Prior to 1997, drugs approved for adults rarely underwent clinical trials with children due to the high costs of pediatric clinical trials and lower potential for profits in the pediatric market. It is particularly telling that in order to incentivize drug companies to conduct pediatric clinical trials, it was necessary to promulgate regulations to make their medications more profitable in the adult market.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.